The roles of glucagon and adrenal epinephrine in mediating bombesininduced central hyperglycemia were further studied in anesthetized rats. Bombesin (10-9mol) injected into the third cerebral ventricle produced an increase in plasma concentrations of glucose, glucagon, and epinephrine. Prior bilateral adrenalectomy completely prevented the hyperglucagonemic and hyperglycemic responses to third cerebral ventricle injection of bombesin. These results support the view that bombesin-induced increases in plasma glucose and glucagon are fully dependent on adrenal epinephrine secretion. Furthermore, during constant intravenous infusion of somatostatin, the hyperglycemic response to third cerebral ventricle injection of bombesin was not significantly influenced despite complete inhibition of the increase in plasma glucagon. Therefore, it is suggested that bombesin-induced central hyperglycemia is mainly mediated by epinephrine itself rather than via epinephrine-stimulated glucagon secretion.
Bombesin, a tetradecapeptide, has been reported to produce a central nervous system (CNS)-mediated hyperglycemia associated with hyperglucagonemia and relative (or absolute) hypoinsulinemia (Brown et al., 1977; Iguchi et al., 1984; Gunion et al., 1984) . In addition, this bombeisninduced increase in plasma glucose and glucagon concentrations has been demonstrated to be fully dependent on adrenal epinephrine secretion (Brown et al., 1977 and .
Since both glucagon and epinephrine can iuduce hyperglycemia, the effect of epinephrine may be mediated either by epinephrine itself or via stimulation of glucagon secretion. M. Brown et al. (1979) have suggested that endogenously secreted epinephrine after the injection of bombesin into the CNS produces hyperglycemia mainly via stimulation of glucagon secretion. On the other hand, it has been reported that exogenously infused epinephrine can stimulate hepatic glucose output independent of any effect on insulin or glucagon secretion (Sacca et al., 1978; Rizza et al., 1979; Cherrington et al., 1984) .
We recently reported that neostigmine injected into the third cerebral ventricle stimulated the secretion of epinephrine, which in turn resulted in producing hyperglycemia in the absence of a rise in the plasma glucagon concentration during constant intravenous infusion of somatostatin (Iguchi et al., 1986) . Thus, the present study was aimed to further examine whether bombesin-induced central hyperglycemia was due to secreted einephrine itself, or mediated via epinephrine-stimulated glucagon secretion. continued to increase until 120min. The IRG concentration reached a peak value 30min after the injection and then decreased gradually. The epinephrine concentration increased significantly 30min after the injection and maintained significantly high values until 120 min. No significant differences in plasma IRI or norepinephrine concentrations were observed between the rats injected with bombesin and those injected with saline. Hepatic venous plasma concentrations of glucose, IRG, and IRI after the bombesin (10-9mol) injection into the third cerebral ventricle remained stable throughout the series of experiments in the bilateral adrenalectomized rats. There were no significant differences in plasma glucose, IRG, and IRI concentrations between the adrenalectomized rats injected with bombesin and those injected with saline.
Thus, bombesininduced increases in plasma IRG and glucose concentrations were completely abolished by prior bilateral adrenalectomy. These results are summarized in Fig. 2 . Fig. 3 shows the effects of somatostatin infusion on glucose and IRG responses to bombesin. During constant intravenous infusion of somatostatin, the hepatic venous plasma glucose concentrations significantly Fig. 3 with Fig . 1 
Discussion
Bombesin is well known as a neuropeptide producing hyperglycemia through the stimulation of the CNS in rats (Brown et al., 1977 and Iguchi et al., 1984; Gunion et al., 1984) and dogs (Brown 1983) . In 1977, M. Brown et al. reported that bombesin injected into the cisternum magnum of rats produced hyperglycemia in doses which were much smaller than those required with intravenous injection. Thereafter, bombesin-induced central hyperglycemia has also been observed in rats after injecting bombesin into the lateral cerebral ventricle (Brown et al., 1979) , or into the hypothalamus (Iguchi et al., 1984) . Futhermore, this hyperglycemia has been shown to be accompanied by hyperglucagonemia and relative (or absolute) hypoinsulinemia (Brown el al., 1977 and Iguchi et al., 1984) . Consistent with these reports, the present study also indicates that bombesin injected into the third cerebral ventricle produces hyperglycemia with hyperglucagonemia and relative hypoinsulinemia.
M. Brown et al.(1979) have demonstrated that bombesin administered into the CNS causes an increase in plasma epinephrine but not plasma corticosterone. They (Brown et al. 1977 and have also reported that prior adrenalectomy but not hypophysectomy completely prevents hyperglycemia and hyperglucagonemia after intracisternal injection of bombesin.
In the present study, bombesin injected into the third cerebral ventricle stimulated the secretion of epinephrine, and prior bilateral adrenalectomy completely abolished bombesininduced hyperglucagonemia and hyperglycemia. These results are in agreement with the above findings of M. Brown et al. and support the view that bombesininduced increases in plasma glucose and glucagon are fully dependent on adrenal epinephrine secretion.
Thus, the increase in plasma glucose and glucagon concentrations after third cerebral ventricle injection of bombesin is secondary to adrenal epinephrine secretion. However, two possible mechanisms by which endogenously secreted epinephrine after bombesin results in producing hyperglycemia are postulated. First, increased epinephrine itself results in development of hyperglycemia independent of glucagon secretion (Sacca et al., 1978; Rizza et al ., 1979; Cherrington et at., 1984) . Second , the rise in plasma epinephrine produces hyperglycemia by virtue of its action in increasing plasma glucagon (Ezdinli and Sokal 1966; Gerich et al., 1976; Chideckel et al ., 1977) . In the present study, during constant intravenous infusion of somatostatin , the increase in plasma glucagon after third cerebral ventricle injection of bombesin was completely inhibited, whereas the hyperglycemic response to bombesin was not significantly influenced. If bombesin-induced central hyperglycemia is mediated by epinephrineinduced glucagon secretion , somatostatin should prevent this hyperglycemia (Weir et al.,1974; Gerich et al ., 1976) . Our observation therefore suggests that bombesin injected into the third cerebral ventricle can cause hyperglycemia independent of glucagon secretion.
Although it has not yet been thoroughly clarified whether or not somatostatin itself directly affects the rates of either glucose uptake or glucose production (Cherrington et al ., 1977; Sacca et al., 1979) , our previous report (Iguchi et al., 1986) demonstrated that the hyperglycemic response to endogeneously secreted epinephrine is not influenced by this constant somatostain infusion . Furthermore, bombesin-induced hyperglycemia was not observed in bilateral adrenalectomized rats with constant somatostatin infusion , supporting the theory that the hyperglycemic response to bobesin is dependent on the secretion of epinephrine. Thus, it is suggested that endogeneously secreted epinephrine induced hyperglycemia after third cerebral ventricle injection of bombesin is mediated by epinephrine itself rather than via its stimulatory effect on glucagon secretion. However, in this in vivo study, despite no significant effect of somatostatin infusion on bombesin-induced hyperglycemia, we cannot completely exclude the possibility that the hyperglycemic effect induced by third cerebral ventricle injection of bombesin may, in very small part, be the result of the increased plasma glucagon concentration.
On the other hand, M. Brown et al. (1979) have suggested that epinephrineinduced hyperglucagonemia is mainly responsible for bombesin-induced central hyperglycemia because systemic bolus administration of somatostatin aboilshed hyperglucagonemic and hyperglycemic responses to the intracisternal injection of bombesin. Although the reason for the difference between their results and ours in the present study is not clear, it appears unlikely that the different injection sites of bombesin (third cerebral ventricle vs. cisternum magnum) and the different methods of anesthesia (pentobarbital vs. ether) may be responsible for the different results, because the two studies have similar effects on the secretion of epinephrine and epinephrine-induced glucagon. However, it is not unreasonable to propose that the different methods of somatostatin administration (constant infusion vs. bolus injection) may explain the different results in the two studies. Systemic bolus injection of somatostatin with a large dose might interfere with the effect of epinephrine independent of glucagon availability (Sacca et al., 1979) . Moreover, the regimen of somatostatin administration might inhibit the hyperglycemic effect of bombesin within the CNS, because the hyperglycemic response to bombesin injected centrally has been reported to be suppressed by the central administration of somatostatin (Brown et al., 1980 and 1983) . We think that the constant intravenous infusion method is more effective, because the duration of the action of a single dose of somatostatin is brief.
In conclusion, the present studies indicate that bombesin injected into the third cerebral ventricle stimulates the secretion of epinephrine, which in turn results in producing hyperglycemia independent of epinephrine-stimulated glucagon secretion in anesthetized rats.
